title: Medicinal chemistry of A2A adenosine receptor antagonists.
abstract: Due to the clearly demonstrated receptor-receptor interaction between adenosine A(2A) and dopamine D(2) receptors in the basal ganglia, the discovery and development of potent and selective A(2A)adenosine receptor antagonists became, in the last ten years, an attractive field of research to discovery new drugs for the treatment of neurodegenerative disorders, such as Parkinsons disease. Different compounds have been deeply investigated as A(2A) adenosine receptor antagonists, which could be classified in two great families: xanthine derivatives and nitrogen poliheterocyclic systems. These studies led to the discovery of some highly potent and selective A(2A) adenosine receptor antagonists such as ZM241385, SCH58261 and some xanthine derivatives (KW6002), which have been used as pharmacological tools for studying this receptor subtype. However, those compounds showed some problems that do not permit their use in clinical studies, such as poor water solubility (SCH58261, and xanthine derivatives) or good affinity for A(2B) adenosine receptor subtype (ZM241385). In the last few years great efforts have been made to overcome these problems, trying to optimize not only the pharmacological profile but also the pharmacokinetic character of this class of compounds. The aim of this report is to briefly summarize the recent progress made in this attractive field of research.
authors.affiliation: Dipartimento di Scienze Farmaceutiche, Università di Ferrara, Via Fossato di Mortasa 17/19, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Cacciari
authors.forename: Giorgia
authors.initials: G
authors.lastname: Pastorin
authors.forename: Giampiero
authors.initials: G
authors.lastname: Spalluto
mesh_terms: D015195:Drug Design; D006571:Heterocyclic Compounds / Q000737:chemistry* / Q000494:pharmacology; D006801:Humans; D019636:Neurodegenerative Diseases / Q000188:drug therapy; D058915:Purinergic P1 Receptor Antagonists; D043705:Receptor, Adenosine A2A; D013329:Structure-Activity Relationship; D014230:Triazoles / Q000737:chemistry* / Q000494:pharmacology; D014970:Xanthines / Q000737:chemistry* / Q000494:pharmacology
chemical_list: D006571:Heterocyclic Compounds; D058915:Purinergic P1 Receptor Antagonists; D043705:Receptor, Adenosine A2A; D014230:Triazoles; D014970:Xanthines